// App-Quantinova.ai

5049 : A phase I/II study of cabazitaxel (Cbz) combined with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after docetaxel (D) chemotherapy: Preliminary results.

Researchers

Presenter

  • Christophe Massard

Principal Investigators

  • Carmel Pezaro

  • Dmitri Bobilev

  • Johann Sebastian De Bono

  • Aurelius Gabriel Omlin

  • Diletta Bianchini

  • David Lorente Estelles

  • Laurence Albiges

  • Yohann Loriot

  • Andrea Varga

  • Thi Xuan Quyen Nguyen

  • Karim Fizazi

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Sanofi, Chilly-Mazarin, France

  • Sanofi-Aventis, Cambridge, MA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Cabazitaxel

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01511536

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved